別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　永井　展裕　東北大学大学院医学系研究科 助教

D．考察

クロトリマゾールはイミダゾール系の抗真菌薬であり、皮膚真菌症の治療に使われている。今回、網膜神経節細胞と網膜色素上皮細胞の低酸素・低栄養負荷培養に対して、10μMから50μMの範囲でDose-dependentに細胞保護作用を示すことがわかった。さらにクロトリマゾールは低酸素・低栄養負荷培養で産生するROSを抑制する可能性を示した。また、デバイス化によってクロトリマゾールの徐放が可能であることを示した。

これらの結果は、クロトリマゾールの網膜保護剤としての新規薬効を示しており、さらに徐放デバイス化によって、投与量を調整して副作用を抑制できる可能性があり、眼疾患への適用可能性を示している。

E．結論

クロトリマゾールの網膜保護剤としての可能性を示した。

F．健康危険情報

該当なし

G．研究発表

1．論文発表

1. Hideyuki Onami,† **Nobuhiro Nagai**,† Hirokazu Kaji, Matsuhiko Nishizawa, Yasufumi Sato, Noriko Osumi, Toru Nakazawa, Toshiaki Abe (†equal contribution). “Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally induced choroidal neovascularization” ***PLoS ONE, 8(3)****, e58580, (2013).*
2. Hideyuki Onami, **Nobuhiro Nagai**, Shigeki Machida, Norihiro Kumasaka, Ryosuke Wakusawa, Yumi Ishikawa, Hikaru Sonoda, Yasufumi Sato, Toshiaki Abe. “Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes” ***RETINA The Journal of Retinal and Vitreous Diseases, 32(6)****, 1204-1213 (2012).*
3. Yumi Ishikawa, **Nobuhiro Nagai**, Hideyuki Onami, Norihiro Kumasaka, Ryosuke Wakusawa, Hikaru Sonoda, Yasufumi Sato, Toshiaki Abe. “Vasohibin-1 and retinal pigment epithelium” ***Adv Exp Med Biol, 723****, 305-310 (2012).*

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　永井　展裕　東北大学大学院医学系研究科 助教

2. 学会発表

（国際学会発表）

1. Toshiaki Abe, Yumi Ishikawa, Hideyuki Onami, Yuki Katsukura, **Nobuhiro Nagai** "Intra-scleral transplantation of collagen sheet with cultured brain-derived neurotrophic factor expressing cells partially rescued the retina from the damage of acute high intraocular pressure" *RD2012 XV International Symposium on Retinal Degeneration, Bad Gogging, Bavaria, Germany* (July 16-21, 2012)
2. **Nobuhiro Nagai**, Hideyuki Onami, Hirokazu Kaji, Takuya Yamada, Yuki Katsukura, Machiko Sato, Yumi Ishikawa, Toru Nakazawa, Matsuhiko Nishizawa, and Toshiaki Abe "Protective Effects of Transscleral Drug Delivery Device Against Light-induced Retinal Damage in Rats" *2012 ARVO annual meeting, Fort Lauderdale, Florida* (May 6-10, 2012)
3. Hideyuki Onami, **Nobuhiro Nagai**, Ryosuke Wakusawa , Hirokazu Kaji, Takuya Yamada, Yumi Ishikawa, Matsuhiko Nishizawa, Yasufumi Sato, Toru Nakazawa,and Toshiaki Abe "Suppression of Rat Choroidal Neovascularization by Transscleral Vasohibin-1 Delivery Device" *2012 ARVO annual meeting, Fort Lauderdale, Florida* (May 6-10, 2012)

（国内学会発表）

1. 永井展裕：「薬剤徐放デバイスの作製と経強膜投与による網膜保護」第 5 回 RRM（Retina Research Meeting）、東京医療センター（2012 年 12 月 8 日）
2. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、小柳恵理、西澤松彦、阿部俊明：「経強膜マルチドラッグ徐放デバイスの作製と網膜保護効果の検討」日本バイオマテリアル学会シンポジウム 2012、仙台国際センター（2012 年 11 月 26-27 日）
3. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、小柳恵理、西澤松彦、阿部俊明：「薬物徐放デバイスの作製と網膜光障害モデルに対する網膜保護効果の検討」第 32 回日本眼薬理学会学術集会、ピアザ淡海（2012 年 9 月 15 日～16 日）
4. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、小柳恵理、西澤松彦、阿部俊明：「網膜光障害モデルに対する経強膜 DDS の網膜保護効果」第 28 回日本 DDS 学会学術集会、札幌コンベンションセンター（2012 年 7 月 4 日～5 日）
5. 大浪英之、永井展裕、梶弘和、西澤松彦、涌沢亮介、佐藤靖史、中澤徹、阿部俊明：「分子徐放デバイス作製と網膜保護」第 63 回東北臨床超微形態懇話会、東北大学医学部（2012 年 6 月 28 日）
6. 永井展裕：「経強膜ドラッグデリバリーによる網膜保護の試み」2011 年度視覚先端医療学講座報告会（2012 年 4 月 9 日）

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　永井　展裕　東北大学大学院医学系研究科 助教

7. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、佐藤真智子、中澤徹、西澤松彦、阿部俊明：「網膜光障害モデルに対する経強膜ドラッグデリバリーデバイスの網膜保護効果」第16回日本眼科学会総会、東京国際フォーラム（2012年4月5日～8日）
8. 大浪英之、永井展裕、梶弘和、西澤松彦、涌沢亮介、佐藤靖史、中澤徹、阿部俊明：「経強膜 vasohibin 徐放デバイスによるラット脈絡膜新生血管抑制」第16回日本眼科学会総会、東京国際フォーラム（2012年4月5日～8日）

H．知的財産権の出願・登録状況
（予定を含む。）

1. 特許取得
なし

2. 実用新案登録
なし

3.その他
なし

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と網膜保護用デバイスの開発に関する研究

研究分担者　西澤松彦　東北大学大学院工学研究科　教授

研究要旨：
本研究は、比較的短期間で実現可能な既存薬や安全性が担保された薬剤ライブラリーを用いた神経保護薬剤スクリーニングとドラックデリバリーシステム（DDS）を確立することが目的である。分担研究として H24 年度は前年度から引き続き、将来的に人に応用するための検討として、微細加工法によるデバイス形状の最適化方法を検討した。また、網膜変性モデル動物としてウサギを使用するため、ウサギ眼用デバイスの作成を検討した。また、強膜上に固定するデザインを検討した。その結果、ウサギ眼に移植可能なデバイスを作成し、薬剤徐放部分が黄斑部まで届いていることを確認した。また、デバイスに溝をつけることで、縫合糸によって強膜上に固定できることがわかった。

A．研究目的

本研究は、比較的短期間で実現可能な既存薬や安全性が担保された薬剤ライブラリーを用いた神経保護薬剤スクリーニングとドラックデリバリーシステム（DDS）を確立することが目的である。将来的に人に応用するための検討として、微細加工法によってデバイス形状を最適化する方法を検討した。また、網膜変性モデル動物としてウサギを使用するため、ウサギ眼用デバイスの作成を検討した。また、強膜上へのデバイス固定方法を検討した。

微細加工は切削装置のMicroMC-2（PMT Co.）を使用した。これはマイクロ単位でアクリル板上にCAD（Computer aided design）でデザインした設計図を切削することができる。デバイスの形状をCADで作製し、アクリル板に掘って鋳型を作製し、これをもとにPDMS（ポリジメチルシロキサン）に鋳型を転写し、この2次鋳型を用いて、DDSの基材であるPEGDM(ポリエチレングリコールジメタクリレート)を光重合し、デバイスを作製している。

B．研究方法

１．デバイス作製用PDMS鋳型の作製

アクリル板にデバイスのリザーバー形状を切削した。このアクリル板にPDMSを乗せ、60℃でPDMSを硬化し、リザーバー形状をPDMSに転写した。このPDMSをシラン化処理した。以下、シラン化処理を示す。PDMSをエタノール、蒸留水の順で10分間ずつ超音波洗浄し、オーブンで乾燥した。プラズマアッシャー（YHS-R）で30秒間酸素プラズマ処理を施した。プラズマ処理したPDMSをシャーレに置き、ドラフト内でシラン（1H,1H,2H,2H-PERFLUOROOCTYLTRICHLOROSILANE、WAKO）を2ヶ所に2 μl ずつPDMSに付かないように垂らし、ふたをして１時間以上静置した。

シラン化処理したPDMS上に別のPDMSを乗せて、60℃で硬化した。このPDMS鋳型が最終形である。

２．デバイス（リザーバー）の作製

PDMS鋳型に、TEGDM 1mlに2-Hydroxy-2-methyl-propiophenone 10μlを混合したプレポリマーを流し、UV架橋(25mW/cm2 - 3 min [SEN LIGHTS CORP])した。

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　西澤松彦　東北大学大学院工学研究科　教授

３．ウサギ眼への移植
白色ウサギの強膜上にデバイスを移植し縫合した。定期的に眼底検査を行い、眼内への副作用を検討した。

（倫理面への配慮）
動物実験操作は、ARVOの眼科研究の動物使用に関する声明のガイドラインに従い、東北大学大学院医学系研究科の動物管理委員会の承認を得た。

Ｃ．研究結果
１．デバイス鋳型の作製
CADを利用して、デバイス（リザーバー）鋳型を設計した。直径2センチの球にフィットするようにデザインした。リザーバーは20μLの薬剤ペレットが詰めることができるようにデザインした。また、強膜上に挿入する際に周囲の組織に傷をつけないように、デバイス先端は角のないサークル形状にデザインした。また、デバイスを強膜上に固定するために、縫合糸を引っ掛けるための溝を設計した。昨年度からのデバイス形状の変更点として、眼球周囲組織により影響の少ない流線型デザインを設計した（Fig.1A）。これは、デバイス後端部（Fig 1A左側）が徐々に厚みが薄くなる形状を有している。また、縫合糸を引っ掛ける構造として、横に4つの溝を設けるデザイン（Fig1A）と、デバイス後端上方に2本の溝を設けるデザインを設計した（Fig.1B、赤矢印）。



Fig.1　デバイスのCADデザイン（A:流線型デザイン、B：新規縫合溝デザイン）

２．ウサギ眼への移植検討
ウサギ眼へ移植した結果、リザーバーの薬剤徐放部分は後眼部に届いていることがわかった（Fig2）。また、ウサギ眼の局面にしっかりフィットしていることを確認した。
また、強膜への固定用にデザインした2本の溝に縫合糸がしっかり引っかかり、デバイスが強膜上に固定されていた（Fig.2B、矢印）。

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　西澤松彦　東北大学大学院工学研究科　教授



Fig.2. デバイス移植後のウサギ眼

D．考察

網膜疾患治療では、黄斑部周囲に薬剤を届ける必要があるため、できるだけ後眼部へデバイスのリザーバー部位を挿入する必要がある。また、徐放面が強膜に密着しなければ、Fibrosisが徐放面に侵入し薬剤が吸収されたり、デバイスと強膜の隙間から薬剤が逃げて結膜へ吸収され、薬剤送達効率が悪くなる可能性がある。今回のプロトタイプでは、縫合糸による強膜上への固定が可能となり、強膜への密着が強化された。

今後はモデルドラッグで眼内への移行性、薬物分布を評価し、移行が確認できたら、実際の薬物で網膜変性動物に移植し、治療効果を確認していく。

E．結論

ウサギ眼用のデバイス形状を作成した。今後は網膜変性ウサギへ移植し、治療効果を見る検討を行う。

F．健康危険情報

該当なし

G．研究発表

1．論文発表

1. Hideyuki Onami, Nobuhiro Nagai, Hirokazu Kaji, **Matsuhiko Nishizawa**, Yasufumi Sato, Noriko Osumi, Toru Nakazawa, Toshiaki Abe (†equal contribution). "Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally induced choroidal neovascularization" ***PLoS ONE, 8(3)***, *e58580, (2013).*
2. Takeo Miyake, Keigo Haneda, Syuhei Yoshino and Matsuhiko Nishizawa, Flexible, Layered Biofuel Cells. Biosensors and Bioelectronics, 40 (2013) 45-49.
3. Syuhei Yoshino, Takeo Miyake, Takeo Yamada, Kenji Hata and Matsuhiko Nishizawa. Molecularly Ordered Bioelectrocatalytic Composite inside a Film of Aligned Carbon Nanotubes Advanced Energy Materials, 3 (2013) 60-64.
4. Nagamine K, Kawashima T, Sekine S, Ido Y, Kanzaki M, **Nishizawa M**. Spatiotemporally Controlled Contraction of Micropatterned Skeletal Muscle Cells on a Hydrogel Sheet. ***Lab Chip***;11:513-517, 2012.
5. Ido Y, Takahashi D, Sasaki M, Nagamine K, Miyake T, Jasinski P, **Nishizawa M**. Conducting Polymer Microelectrodes Anchored to Hydrogel Films. ***ACS Macro Let***;1:400-403, 2012.
6. Haneda K, Yoshino S, Ofuji T, Miyake T, **Nishizawa M**. Sheet-Shaped Biofuel Cell Constructed from Enzyme-Modified Nanoengineered Carbon Fabric. ***Electrochim. Acta***;82:175-178, 2012.
7. Nagamine K, Ito K, Takeda M, Otani S, **Nishizawa M**. An Oxygen Responsive Microparticles Patterned Hydrogel Sheet for Enzyme Activity Imaging . ***Electrochemistry***;80:318-320, 2012.

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　西澤松彦　東北大学大学院工学研究科　教授

2. 学会発表

（国際学会発表）

1. M. Nishizawa, K. Nagamine, T. Miyake and H. Kaji “Microfabricated Miniature Biofuel Cells with Nanoengineered Enzyme Electrodes” IUMRS-International Conference on Electronic Materials, Yokohama (Sept.24.2012)
2. Nobuhiro Nagai, Hideyuki Onami, Hirokazu Kaji, Takuya Yamada, Yuki Katsukura, Machiko Sato, Yumi Ishikawa, Toru Nakazawa, **Matsuhiko Nishizawa**, and Toshiaki Abe “Protective Effects of Transscleral Drug Delivery Device Against Light-induced Retinal Damage in Rats” *2012 ARVO annual meeting, Fort Lauderdale, Florida* (May 6-10, 2012)
3. Hideyuki Onami, Nobuhiro Nagai, Ryosuke Wakusawa , Hirokazu Kaji, Takuya Yamada, Yumi Ishikawa, **Matsuhiko Nishizawa**, Yasufumi Sato, Toru Nakazawa,and Toshiaki Abe “Suppression of Rat Choroidal Neovascularization by Transscleral Vasohibin-1 Delivery Device” *2012 ARVO annual meeting, Fort Lauderdale, Florida* (May 6-10, 2012)
4. M. Nishizawa, S. Yoshino and T. Miyake,“Enzyme-CNT Ensemble Films for Miniature Biological Fuel Cells” Biosensors 2012 ,Mexico (May 18.2012)
5. M. Nishizawa, Y. Ido, D. Takahashi, T. Miyake and K. Nagamine,” Conducting Polymer Microelectrodes Printed on Soft, Moist Hydrogels for Effective Stimulation of Muscular and Neuronal Cells” 2012 MRS Spring Meeting ,San Francisco (April 11 ,2012)
6. M. Nishizawa, S. Yoshino, T. Miyake, T. Yamada and K. Hata,” Enzyme-Carbon Nanotube Ensemble Films for Biofuel Cells”, 2012 MRS Spring Meeting ,San Francisco(April 10,2012)

（国内学会発表）

1. 西澤松彦:「シート状バイオ発電システム」日本化学会 93 春季年会 (京都) 平成 25 年 3 月 22 日
2. 西澤松彦 :「ハイドロゲルへの電極形成と応用」第 27 回エレクトロニクス実装学会 (仙台) 平成 25 年 3 月 15 日
3. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、小柳恵理、西澤松彦、阿部俊明 :「経強膜マルチドラッグ徐放デバイスの作製と網膜保護効果の検討」日本バイオマテリアル学会シンポジウム 2012、仙台国際センター（2012 年 11 月 26-27 日）
4. 西澤松彦, 長峯 邦明, 梶 弘和, 神崎展 :「マイクロ電極システムによる培養細胞運動アッセイ」第 29 回医用高分子研究会 (つくば) 平成 24 年 11 月 20 日
5. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、小柳恵理、西澤松彦、阿部俊明 :「薬物徐放デバイスの作製と網膜光障害モデルに対する網膜保護効果の検討」第 32 回日本眼薬理学会学術集会、ピアザ淡海（2012 年 9 月 15 日～16 日）
6. 永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、小柳恵理、西澤松彦、阿部俊明 :「網膜光障害モデルに対する経強膜 DDS の網膜保護効果」第 28 回日本 DDS 学会学術集会、札幌コンベンションセンター（2012 年 7 月 4 日～5 日）

別紙３

厚生労働科学研究費補助金（障害者対策総合研究事業）
分担研究報告書

新規薬剤の生体内スクリーニングシステムの確立と
網膜保護用デバイスの開発に関する研究

研究分担者　西澤松彦　東北大学大学院工学研究科　教授

７．　大浪英之、永井展裕、梶弘和、**西澤松彦**、涌沢亮介、佐藤靖史、中澤徹、阿部俊明:「分子徐放デバイス作製と網膜保護」第 63 回東北臨床超微形態懇話会、東北大学医学部（2012 年 6 月 28 日）

８．　永井展裕、大浪英之、梶弘和、山田琢也、勝倉由樹、佐藤真智子、中澤徹、**西澤松彦**、阿部俊明：「網膜光障害モデルに対する経強膜ドラッグデリバリーデバイスの網膜保護効果」第 16 回日本眼科学会総会、東京国際フォーラム（2012 年 4 月 5 日～8 日）

９．　大浪英之、永井展裕、梶弘和、**西澤松彦**、涌沢亮介、佐藤靖史、中澤徹、阿部俊明：「経強膜 vasohibin 徐放デバイスによるラット脈絡膜新生血管抑制」第 16 回日本眼科学会総会、東京国際フォーラム（2012 年 4 月 5 日～8 日）

H．知的財産権の出願・登録状況
（予定を含む。）

1. 特許取得
なし

2. 実用新案登録
なし

3.その他
なし

別紙４

研究成果の刊行に関する一覧表（阿部　俊明）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Toshiaki Abe, Yumi Tokita-Ishikawa, Hideyuki Onami, Yuki Katsukura, Hirokazu Kaji, Matsuhiko Nishizawa, Nobuhiro Nagai	Intra-scleral transplantation of collagen sheet with cultured brain-derived neurotrophic factor expressing cells partially rescued the retina from the damage of acute high intraocular pressure	Adv Exp Med Biol			in press
Onami H, Nagai N, Kaji H, Nishizawa M, Sato Y, Osumi N, Nakazawa T, Abe T	Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization	PLoS One	8(3)	e58580	2013
Ahmed Y Shanab, Toru Nakazawa, Morin Ryu, Yuji Tanaka, Noriko Himori, Keiko Taguchi, Masayuki Yasuda, Ryo Watanabe, Jiro Takano; Saido Takaomi, Naoko Minegishi; Toshio Miyata, Toshiaki Abe, Masayuki, Yamamoto	Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor	Neurobiol Dis	48(3)	556-67	2012 Dec
Hiroshi Kunikata, Masayuki Yasuda, Naoko Aizawa, Yuji Tanaka, Toshiaki Abe, and Toru Nakazawa	Intraocular Concentrations of Cytokines and Chemokines in Rhegmatogenous Retinal Detachment and the Effect of Intravitreal Triamcinolone Acetonide	Am J Ophthalmol	155(6)	1028-1037	2013 Jun;
Aizawa N, Kunikata H, Abe T, Nakazawa T	Efficacy of combined 25-gauge microincision vitrectomy, intraocular lens implantation, and posterior capsulotomy	J Cataract Refract Surg	38(9)	1602-7	2012 Sep
Kobayashi W, Abe T, Tamai H, Nakazawa T.	Choroidal excavation with polypoidal choroidal vasculopathy: a case report.	Clin Ophthalmol	6	1373-6	2012
Hideyuki Onami, Nobuhiro Nagai, Shigeki Machida, Norihiro Kumasaka, Ryosuke Wakusawa, Yumi Ishikawa, Hikaru Sonoda, Yasufumi Sato, Toshiaki Abe	Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes	Retina	32(6)	1204-13	2012 Jun
Yumi Tokita-Ishikawa, Nobuhiro Nagai, Hideyuki Onami, Norihiro Kumasaka, Hikaru Sonoda, Tomoaki Takakura, Yasufumi Sato, Toshiaki Abe	Vasohibin and retinal pigment epithelium	Adv Exp Med Biol	723	305-310	2012

別紙４

研究成果の刊行に関する一覧表（阿部　俊明）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
浅野俊一郎、阿部俊明、國方彦志、今留尚人、高橋麻衣、中澤徹	右眼に急性網膜壊死を発症した16年後に左眼にも発症した1例	臨床眼科			2013．印刷中
相澤奈帆子、國方彦志、岡村知世子、阿部俊明、中澤徹	25G 硝子体手術中の脈絡膜剥離	眼科臨床紀要	5(8)	792-796	2012.8
金澤紘子、國方彦志、安田正幸、新田文彦、鬼怒川次郎、阿部俊明、中澤徹	特発性黄斑円孔に対する硝子体手術成績とトリアムシノロンアセトニドの効果	臨床眼科	66(8)	1219-1224	2012.8
伊藤梓、國方彦志、阿部俊明、安田正幸、中澤徹	黄斑円孔術後に発症した脈絡膜新生血管の一例	眼科臨床紀要	5(9)	855-859	2012

別紙４

研究成果の刊行に関する一覧表（中澤　徹）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takahashi H, Sugiyama T, Tokushige H , Maeno T, Nakazawa T, Ikeda T, Araie M	Comparison of CCD-equipped laser speckle flowgraphy with hydrogen gas clearance method in the measurement of optic nerve head microcirculation in rabbits Experimental Eye Research	Exp Eye Res.		108	2013
Toshio Hisatomi, Shintaro Nakao, Yusuke Murakami, Kousuke Noda, Toru Nakazawa, Shoji Notomi, Edward Connolly, Haicheng She, Lama Almulki, Yasuhiro Ito, Demetrios G. Vavvas, Tatsuro Ishibashi, Joan W. Miller	The Regulatory Roles of Apoptosis-Inducing Factor in the Formation and Regression Processes of Ocular Neovascularization	The American Journal of Pathology	181(1)	53-61	2012.
Shin Takayama, Masashi Watanabe, Hiroko Kusuyama, Satoru Nagase, Takashi Seki, Toru Nakazawa, Nobuo Yaegashi	Evaluation of the Effects of Acupuncture on Blood Flow in Humans with Ultrasound Color Doppler Imaging	Evidence-Based Complementary and Alternative Medicine		513638	2012
Ai Shimizu, Yoshimasa Takano, Dong Shi, Shunji Yokokura, Yu Yokoyama, Xiaodong Zheng, Atsushi shiraishi, Yuichi Ohashi, Toru Nakazawa, Nobuo Fuse	Evaluation of CNTNAP2 gene polymorphisms for exfoliation syndrome in Japanese	Molecular Vision	18	1395-1401	2012
Shanab AY, Nakazawa T, Ryu M, Tanaka Y, Himori N, Taguchi K, Yasuda M, Watanabe R, Takano J, Saido T, Minegishi N, Miyata T, Abe T, Yamamoto M	Metabolic stress response implicated in diabetic retinopathy: The role of calpain, and the therapeutic impact of calpain inhibitor	Neurobiol Dis	48(3)	556-567	2012 Dec
Aizawa N, Kunikata H, Abe T, Nakazawa T	Efficacy of combined 25-gauge microincision vitrectomy, intraocular lens implantation, and posterior capsulotomy	J Cataract Refract Surg	38(9)	1602-1607	2012

別紙４

研究成果の刊行に関する一覧表（中澤　徹）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takano Y, Shi D, Shimizu A, Funayama T, Mashima Y, Yasuda N, Fukuchi T, Abe H, Ideta H, Zheng X, Shiraishi A, Ohashi Y, Nishida K, Nakazawa T, Fuse N	Association of Toll-like Receptor 4 Gene Polymorphisms in Japanese Subjects With Primary Open-Angle, Normal-Tension, and Exfoliation Glaucoma	Am J Ophthalmol.	154(5)	825-832	2012
Kunikata H, Aizawa N, Meguro Y, Abe T and Nakazawa T	Combined 25-gauge microincision vitrectomy and toric intraocular lens implantation with posterior capsulotomy	J Cataract Refract Surg	38(9)	1602-1607	2012
Shimura M, Yasuda K, Yasuda M, Nakazawa T	Visual Outcome After Intravitreal bevacizumab depends on the optical coherence tomographic patterns of patterns with diffuse diabetic macular edema.	Retina			2012 Dec 5

別紙４

研究成果の刊行に関する一覧表（植田　弘師）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Halder SK, Matsunaga H, Yamaguchi H, Ueda H	Novel neuroprotective action of prothymosin alpha-derived peptide againstretinal and brain ischemic damages.	J Neurochem			2013 in press.
Halder SK, Sugimoto J, Matsunaga H, Ueda H	Therapeutic benefits of 9-amino acid peptide derived from prothymosin alpha against ischemic damages	Peptides			2013 in press
Halder SK, Ueda H	Regional distribution and cell type-specific subcellular localization of Prothymosin a in brain	Cell Mol Neurobiol	32	59-66	,2012
Halder SK, Matsunaga H, Ueda H	Neuron-specific non-classical release of prothymosin alpha: a novel neuroprotective damage-associated molecular patterns	J Neurochem	123	262-275	2012
Ueda H, Matsunaga H, Halder SK	Prothymosin α plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms	Ann N Y Acad Sci	1269	34-43	2012

別紙４

研究成果の刊行に関する一覧表（永井　展裕）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hideyuki Onami,† Nobuhiro Nagai,† Hirokazu Kaji, Matsuhiko Nishizawa, Yasufumi Sato, Noriko Osumi, Toru Nakazawa, Toshiaki Abe (†equal contribution).	Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally induced choroidal neovascularization	PLoS ONE,	8(3)	e58580	2013
Hideyuki Onami, Nobuhiro Nagai, Shigeki Machida, Norihiro Kumasaka, Ryosuke Wakusawa, Yumi Ishikawa, Hikaru Sonoda, Yasufumi Sato, Toshiaki Abe	Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes	RETINA The Journal of Retinal and Vitreous Diseases	32(6)	1204-1213	2012
Yumi Ishikawa, Nobuhiro Nagai, Hideyuki Onami, Norihiro Kumasaka, Ryosuke Wakusawa, Hikaru Sonoda, Yasufumi Sato, Toshiaki Abe	Vasohibin-1 and retinal pigment epithelium	Adv Exp Med Biol	723	305-310	2012

別紙４

研究成果の刊行に関する一覧表（西澤　松彦）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hideyuki Onami,† Nobuhiro Nagai,† Hirokazu Kaji, Matsuhiko Nishizawa, Yasufumi Sato, Noriko Osumi, Toru Nakazawa, Toshiaki Abe (†equal contribution).	Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally induced choroidal neovascularization	PLoS ONE,	8(3)	e58580	2013
Takeo Miyake, Keigo Haneda, Syuhei Yoshino and Matsuhiko Nishizawa	Flexible, Layered Biofuel Cells.	Biosensors and Bioelectronics	40	45-49	2013
Syuhei Yoshino, Takeo Miyake, Takeo Yamada, Kenji Hata and Matsuhiko Nishizawa	Molecularly Ordered Bioelectrocatalytic Composite inside a Film of Aligned Carbon Nanotubes	Advanced Energy Materials	3	60-64	2013
Nagamine K, Kawashima T, Sekine S, Ido Y, Kanzaki M, Nishizawa M	Spatiotemporally Controlled Contraction of Micropatterned Skeletal Muscle Cells on a Hydrogel Sheet	Lab Chip	11	513-517	2012
Ido Y, Takahashi D, Sasaki M, Nagamine K, Miyake T, Jasinski P, Nishizawa M	Conducting Polymer Microelectrodes Anchored to Hydrogel Films	ACS Macro Lett	1	400-403	2012
Haneda K, Yoshino S, Ofuji T, Miyake T, Nishizawa M	Sheet-Shaped Biofuel Cell Constructed from Enzyme-Modified Nanoengineered Carbon Fabric	Electrochim. Acta	82	175-178	2012
Nagamine K, Ito K, Takeda M, Otani S, Nishizawa M	An Oxygen Responsive Microparticles Patterned Hydrogel Sheet for Enzyme Activity Imaging	Electrochemistry	80	318-320	2012

OPEN ACCESS Freely available online

PLOS | ONE

Transscleral Sustained Vasohibin-1 Delivery by a Novel Device Suppressed Experimentally-Induced Choroidal Neovascularization

Hideyuki Onami[1,2☯], Nobuhiro Nagai[1☯], Hirokazu Kaji[3], Matsuhiko Nishizawa[3], Yasufumi Sato[4], Noriko Osumi[5], Toru Nakazawa[2], Toshiaki Abe[1*]

1 Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, Sendai, Japan, **2** Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan, **3** Department of Bioengineering and Robotics, Graduate School of Engineering, Tohoku University, Sendai, Japan, **4** Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, **5** Division of Developmental Neuroscience, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, Sendai, Japan

Abstract

We established a sustained vasohibin-1 (a 42-kDa protein), delivery device by a novel method using photopolymerization of a mixture of polyethylene glycol dimethacrylate, triethylene glycol dimethacrylate, and collagen microparticles. We evaluated its effects in a model of rat laser-induced choroidal neovascularization (CNV) using a transscleral approach. We used variable concentrations of vasohibin-1 in the devices, and used an enzyme-linked immunosorbent assay and Western blotting to measure the released vasohibin-1 (0.31 nM/day when using the 10 μM vasohibin-1 delivery device [10VDD]). The released vasohibin-1 showed suppression activity comparable to native effects when evaluated using endothelial tube formation. We also used pelletized vasohibin-1 and fluorescein isothiocyanate-labeled 40 kDa dextran as controls. Strong fluorescein staining was observed on the sclera when the device was used for drug delivery, whereas pellet use produced strong staining in the conjunctiva and surrounding tissue, but not on the sclera. Vasohibin-1 was found in the sclera, choroid, retinal pigment epithelium (RPE), and neural retina after device implantation. Stronger immunoreactivity at the RPE and ganglion cell layers was observed than in other retinal regions. Significantly lower fluorescein angiography (FA) scores and smaller CNV areas in the flat mounts of RPE-choroid-sclera were observed for the 10VDD, VDD (1 μM vasohibin-1 delivery device), and vasohibin-1 intravitreal direct injection (0.24 μM) groups when compared to the pellet, non-vasohibin-1 delivery device, and intravitreal vehicle injection groups. Choroidal neovascularization can be treated with transscleral sustained protein delivery using our novel device. We offer a safer sustained protein release for treatment of retinal disease using the transscleral approach.

Citation: Onami H, Nagai N, Kaji H, Nishizawa M, Sato Y, et al. (2013) Transscleral Sustained Vasohibin-1 Delivery by a Novel Device Suppressed Experimentally-Induced Choroidal Neovascularization. PLoS ONE 8(3): e58580. doi:10.1371/journal.pone.0058580

Editor: Olaf Strauß, Eye Hospital, Charité, Germany

Received August 11, 2012; **Accepted** February 6, 2013; **Published** March 5, 2013

Funding: This work was supported in part by Grant-in-Aid for Scientific Research (No. 21592214) and Young Scientists (A) (No. 23680054) from the Ministry of Education, Culture, Sports, Science, and Technology, Health Labour Sciences Research Grant from the Ministry of Health Labour and Welfare (No. H23-iryokiki-wakate-003, H23-kankaku-ippan-004, H24-nanchitoh-ippan-067), the Suzuken Memorial Foundation, and the Ichiro Kanehara Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: toshi@oph.med.tohoku.ac.jp

☯ These authors contributed equally to this work.

Introduction

Age-related macular degeneration (AMD) is a well-known sight-threatening disease in developed countries [1]. Although many treatment regimens have been used to treat AMD [2–6], intravitreal injection of anti-vascular endothelial growth factor (VEGF) produced lesion improvement and better visual acuity in some patients [7,8]. However, intra-vitreal injection of anti-VEGF also produced irritation, infection, and other adverse side effects [9]. Further, that treatment required repeated injections, usually occurring once a month [7,8]. Thus, other types of drugs or drug delivery systems (DDSs) need to be developed to treat AMD.

Eye drops and systemic drug administration are unsuitable for retinal diseases if the physician is looking for effective drug penetration into the eye, especially for macular diseases such as AMD [10,11]. Although drug delivery device implantation into the vitreous showed effective delivery of drug to the retina, these treatments may cause severe side effects, such as infection, vitreous hemorrhage, or retinal detachment [12–14]. Drug delivery using viral vectors has been attempted for treatment of devastating retinal diseases [15]; however, this method may induce immune cell or humoral responses [16,17].

Subconjunctival drug delivery is less invasive than intravitreal drug injection and can deliver more drug than seen with eye drops or systemic administration [10,11]. There are published data investigating clinical use of subconjunctival drug administration [18,19]. Thus, the subconjunctival route may be an attractive method for drug delivery to the retina. The major difficulties with subconjunctival DDS are uncontrollable release of the target drug [20], as well as an unknown drug delivery route and mechanism to

reach the retina [20,21]. Sustained release, with no drug bolus effect, would be required to reduce side effects [22,23].

We previously reported our results of the use of a novel drug delivery device placed on the sclera that we thought would be an effective tool in treating retinal diseases [24]. The device consisted of a drug-releasing semi-permeable membrane and impermeable membranes acting as the drug reservoir. Because of the non-biodegradable and one-way release nature of the device, we could achieve sustained release of the drug to the retina. We examined the effects of this device using a laser-induced choroidal neovascularization (CNV) model in rats.

Anti-VEGF antibody is a well-known treatment agent in CNV therapy, but suppression of VEGF function may induce many harmful effects in physiological function [25]. We selected vasohibin-1 for the loading drug in the device in this study because of its well-known anti-angiogenic activity [26,27]. Vasohibin-1 is a 42-kDa polypeptide, a VEGF-inducible molecule expressed by cultured human endothelial cells (ECs) [26]. Vasohibin-1 inhibits the formation of EC networks *in vitro*, corneal neovascularization *in vitro* [26], retinal neovascularization in a mouse model of oxygen-induced ischemic retinopathy [27], and laser-induced mouse [25] and monkey CNV [28]. Each of the *in vivo* studies treated the tissue by direct intravitreal injection of vasohibin-1.

Here we shall show that continuous trans-scleral vasohibin-1 delivery by the device can suppress laser-induced CNV in rat eyes (Fig. 1A) as well as that by intravitreal injection. This technique and device may hold promise for safer and more effective treatment of patients with AMD.

Methods

Vasohibin-1 and Device Preparation

Vasohibin-1 was purified as reported previously [25]. For the preparation of the vasohibin-1 formulation, an 80-μL volume of vasohibin-1 (either 1.25 or 12.5 μM) in vehicle (phosphate buffered saline [PBS] control) was mixed with 20 μL of polyethylene glycol dimethacrylate (PEGDM), then underwent UV curing at an intensity of 11.5 mJ/cm^2 (Lightningcure LCS; Hamamatsu Photonics, Hamamatsu City, Japan) for 3 minutes.

The devices consisted of a semi-permeable drug-releasing membrane and an impermeable reservoir (Fig. 1A, 1B), as we reported previously [24]. The loaded vasohibin-1 doses included vehicle only (identified as NVDD), 1 μM vasohibin-1 (VDD), and 10 μM vasohibin-1 (10VDD), with a total volume of 1.5 μL in each device. The size of the device was 2 mm×2 mm wide ×1 mm high (drug-releasing surface area; 1.5 mm×1.5 mm = 2.25 mm^2) for the rat experiments (Fig. 1B, device) and 4 mm×4 mm×1.5 mm (drug-releasing surface area; 3.5 mm×3.5 mm = 12.25 mm^2) for the vasohibin-1 releasing *in vitro* assay. The release amount from the transplanted device was small and it was very difficult to detect released vasohibin-1 by the standard ELISA technique, so we decided to use a larger device for the ELISA procedure. As a control, we used pelletized vasohibin-1 without the reservoir and permeable membrane (Fig. 1B, pellet). The concentration of pelletized vasohibin-1 was adjusted to be the same concentration as that of the 10VDD (10 μM vasohibin-1). The total amount of vasohibin-1 released from the 10VDD device during the 2-week *in vivo* experiment was aimed to be equivalent to that of the intravitreal vasohibin-1 injection. A FITC-labeled 40 kDa dextran-loaded device (FD40DD) was also used for monitoring the position of the implanted device.

In Vitro Experiments

***1 In Vitro* Release Assay, Enzyme-linked Immunosorbent Assay, and Western Blotting.** The devices loaded with vasohibin-1 were placed in the wells of a 24-well culture plate filled with 200 μL PBS at 37°C. Aliquots (200 μL) of the buffer in each well were collected at Days 1, 7, 14, and 28 during change-out of old buffer for new buffer solution. The collected samples were considered to include only protein for vasohibin-1. We then determined the amount of vasohibin-1 in the buffer using an enzyme-linked immunosorbent assay (ELISA) [29] and western blotting [30]. The intensity of the color of the ELISA reaction products was measured with a microplate reader (MAXline; Molecular Devices Corporation, Sunnyvale, CA, USA). The measurements were made in duplicate, and the mean value was used for comparisons. The 50-μL collected samples and 100 fmol of recombinant vasohibin-1 (positive control) were loaded, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% separating gel, and transferred to nitrocellulose membranes for western blotting. The membranes were blocked for 1 hour at room temperature with 5% ECL blocking agent (GE Healthcare Biosciences, Pittsburgh, PA, USA), and then incubated overnight at 4°C in PBS containing 0.05% Tween 20 (T-PBS), 2.5% skim milk, and 1 μg/mL horseradish peroxidase-conjugated anti–vasohibin-1 monoclonal antibody. The membrane filters were washed 3 times with T-TBS and the blots were detected using an enhanced chemiluminescence method (ECL Western Blotting Detection Kit; Amersham Biosciences, Piscataway, NJ, USA). The results were visualized using an imaging system (ImageQuant LAS-1000; GE Healthcare Biosciences).

2 Endothelial Tube Formation. Endothelial tube formation was assessed with normal human umbilical vein endothelial cells (HUVECs) (Takara Bio; Otsu, Japan) co-cultured on neonatal normal human dermal fibroblasts (NHDF, Takara Bio) layer using anti-human CD31 immunostaining, as reported previously [28]. Two nM vascular endothelial growth factor (VEGF, Wako; Tokyo, Japan) was then added to the endothelial cell growth medium (EGM, Takara Bio) containing no vasohibin-1 (control), and 0.2, 2, or 10 nM vasohibin-1, respectively. VEGF (2 nM) and samples of vasohibin-1 released from the vasohibin-1-loaded device over 3 hours at 37°C were used to examine released vasohibin-1 activity. We collected the released vasohibin-1 from the pellet and used it at a concentration of 0.56 nM (as measured by ELISA). On Day 3, the cells were fixed and stained using an anti-human CD31 immunostaining kit (Kurabo; Tokyo, Japan) according to the manufacturer's instructions. The number of stained HUVECs was determined using a computerized system (Kurabo Angiogenesis Image Analyzer program; Kurabo).

In Vivo CNV Experiments

1 Animals. The procedures used in the animal experiments followed the guidelines of the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research, and they were approved by the Animal Care Committee of Tohoku University Graduate School of Medicine (Permit Number: 2011–136). Twenty Sprague-Dawley (SD) rats (Experiments 1 and 2) and 36 Brown Norway (BN) rats (Experiment 3) weighing between 250 and 300 g were used (Table 1). All animals were followed up to 2 weeks after device transplantation and/or laser burn. We examined the effects of devices either at 1 week or 2 weeks for FA evaluation and 2 weeks for flat-mount evaluation. Macro examination was performed at 1 and 2 weeks after the device transplantation. For all procedures, the rats were anesthetized with an intramuscular



Figure 1. Device and vasohibin-1 release. (A) Schematic image of transscleral sustained vasohibin-1 delivery. We evaluated its effects via transscleral approach for rat laser-induced choroidal neovascularization (CNV). The device consists of a drug pelletized with PEGDM, a reservoir made of TEGDM, and a controlled-release membrane made of PEGDM that contains collagen microparticles. (B) Photograph showing a drug pellet and the delivery device containing a drug pellet. (C) Image of a device placed on the sclera of a rat eye at 3 days after implantation. The amount of vasohibin-1 in the PBS was measured at 1, 7, 14, and 28 days after starting incubation. The representative results of western blotting and the result of ELISA are shown in (D) and (E), respectively. We collected the samples at only the given time points and replaced only the equal volume of PBS. The released vasohibin-1 amounts accumulated for 6, 7, and 14 days. [The pellet samples collected at Day 1 (shown as 1d) were diluted five times due to their concentration before they were evaluated by western blotting]. NVDD: non-vasohibin-1 (vehicle) delivery device, VDD: 1 μM vasohibin-1 delivery device, 10VDD: 10 μM vasohibin-1 delivery device, Pellets: vasohibin-1 pelletized at the same concentration of 10VDD (without reservoir and cover).
doi:10.1371/journal.pone.0058580.g001

injection of ketamine hydrochloride (35 mg/kg) and xylazine hydrochloride (5 mg/kg), and the animals' pupils were dilated with topical 2.5% phenylephrine and 1% tropicamide. Oxybuprocaine hydrochloride (0.4%) was also used for local anesthesia. In all *in vivo* experiments, the animal's left eye was used as a control.

2 Implantation of VDDs, Pellets, and Intravitreal Vasohibin-1 Injection. Devices were implanted subconjunctively in the right eyes of the rats (Table 1). A 4-mm long conjunctival incision was made along the limbus in the upper temporal position. The devices were inserted into the subconjunctival space using forceps, with the drug-releasing surface facing the sclera. The device was placed between the optic disc and the equator, in the posterior quadrant, using no suture to anchor it into place. The conjunctival incision was closed with 9–0 silk and antibiotic ointment was applied to the eyes. Vasohibin-1 protein (0.24 μM) was injected using a 10-μL glass syringe (Hamilton; Reno, NV) 4 days after the experimental CNV procedure. The left eyes were used as untreated controls.

The rats were anesthetized, pupils were dilated, and a fundus examination was performed immediately after the surgery.

Experiment 1: Monitoring the Implanted Devices and Pellets

To monitor the device and drug release, fluorescein isothiocyanate (FITC) dextran (FD40; Sigma-Aldrich) pelletized with PEGDM was prepared and used as a control drug. The FD40 was dissolved in PBS at a concentration of 250 mg/mL and loaded in the device in the same way as vasohibin-1. Eight SD rats were included in this experiment; 4 rats received the FD40 delivery device (FD40DD) and 4 rats received only pelletized FD40.

Experiment 2: Immunohistochemistry after Device Implantation

Immunostaining for vasohibin-1was performed 2 weeks after device implantation. Twelve SD rats were used as follows (Table 1): 4 rats received vehicle (non-vasohibin-1) in the delivery device on the sclera (NVDD), 4 rats received 1.5 μL of 10 μM vasohibin-1 in the delivery device (10VDD), and 4 rats received 1.5 μL of 10 μM vasohibin-1 pellets implanted on the sclera. Immunohistochemistry was performed as reported previously [25].

Animals were euthanized using overdoses of ketamine hydrochloride and xylazine hydrochloride. The eyes were enucleated

Table 1. In Vivo Study Demographics.

Number of animals	Strain	Treatment	Methods	Position of implant
Experiment 1				
4	SD	Untreated	FD40DD	Sclera
4	SD	Untreated	FD40 Pellet	Sclera
Experiment 2				
4	SD	Untreated	NVDD	Sclera
4	SD	Untreated	10VDD	Sclera
4	SD	Untreated	Pellet	Sclera
Experiment 3				
6	BD	CNV	NVDD	Sclera
6	BD	CNV	VDD	Sclera
6	BD	CNV	10VDD	Sclera
6	BD	CNV	Pellet	Sclera
6	BD	CNV	Vehicle	Vitreous
6	BD	CNV	Vasohibin-1	Vitreous

SD: Sprague-Dawley rats, BN: Brown Norway rats, CNV: choroidal neovascularization, NVDD: non-vasohibin-1 delivery device, 10VDD: 10 μM vasohibin-1 delivery device.

doi:10.1371/journal.pone.0058580.t001

and fixed for 12 hours in 4% paraformaldehyde (PFA) at 4°C. The anterior segment and lens were removed from each eye. The posterior segment was cryoprotected at 4°C through successive 12-hour incubations in 10%, 20%, and 30% sucrose dissolved in saline. The tissues were immersed in OCT compound (Tissue-Tec; Sakura Finetec USA, Inc., Torrance, CA, USA) and frozen in acetone in a dry-ice bath. The frozen posterior segment was sectioned at the center of the implanted area at a thickness of 5 μm for each section, using a cryostat. We examined eight continuous sections per eye. The sections were incubated in rabbit polyclonal antibody against human vasohibin-1, followed by FITC-conjugated anti-rabbit IgG (1:200; Dako, Glostrup, Denmark) for 30 minutes. The sections were washed three times with PBS between each step. Negative controls (4 rats) incubated with just FITC-conjugated anti-rabbit IgG were also prepared. Slides were counterstained with 4, 6-diamino-1-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA) and photographed using a fluorescence microscope (Leica FW4000, Ver. 1.2.1; Leica Microsystems Japan, Tokyo, Japan).

Experiment 3: Choroidal Neovascularization Study

A total of 36 BN rats were used (Table 1). The devices and pellets were implanted on the same day as the CNV procedure. The rats were divided into six groups (6 rats in each group): rats with NVDD, rats with 1.5 μL of 1 μM vasohibin-1 in the delivery device (VDD), rats with 1.5 μL of 10 μM vasohibin-1 in the delivery device (10VDD), rats with 1.5 μL of 10 μM vasohibin-1 pellets implanted on the sclera, rats with intravitreal injection of 5 μL of vehicle, and rats with an intravitreal injection of 0.24 μM vasohibin-1 protein occurring 4 days after the experimental CNV procedure. The amount of intravitreal vasohibin-1 used and the day of the injection were determined based on our previous data [25]. The intravitreal injections were performed using a 10-μL glass syringe (Hamilton), and the needle was passed through the sclera just behind the limbus into the vitreous cavity.

3 CNV procedure. A green argon laser was used to rupture the choroidal membrane using a slit-lamp delivery system (Ultima 2000SE; Lumenis, Yokneam, Israel) with a contact lens [31]. The laser settings were: 50 μm diameter for 0.1 sec duration, at an intensity of 650 to 750 mW. Six laser burns were made around the optic disc (Fig. 1A). Each burn was confirmed to have induced subretinal bubbles, indicating a rupture of Bruch's membrane.

In addition to the routine ophthalmological examinations, fluorescein angiography (FA) with an imaging system (GENESIS-Df; Kowa, Tokyo, Japan) was performed at 1 and 2 weeks after the CNV laser burn, and choroidal flat mounts of the CNV site were performed at 2 weeks after the procedure. Two retinal specialists (HO and TA) and one non-specialist (NN) evaluated the angiograms for FA grading evaluation in a blinded manner using a grading system [32], where Grade 1 = no hyperfluorescence; Grade 2 = hyperfluorescence without leakage; Grade 3 = hyperfluorescence in the early or middle phase and leakage in the late phase; and Grade 4 = bright hyperfluorescence in the transit and leakage in the late phase beyond the treated areas. The camera was a handheld retinal camera for photographing humans, and the fact that rat eye optics differ from that of humans made the process somewhat difficult. Intense fluorescein leakage also made the results of photographs as faint. The laser burn sometimes made subretinal hemorrhages that were shown as fluorescein blockage. These results may have influenced the evaluation. We tried to focus on the laser burn as much as possible to not influence the evaluation. Further we also tried to synchronize evaluations as much as possible to avoid significant bias due to fluorescein leakage. Total grades were analyzed for statistical significance.

4 Fluorescein-Labeled Dextran Perfusion and Choroidal Flat-Mount Preparation. The size of the CNV lesion was measured on choroidal flat mounts to examine the effect of the vasohibin-1 delivery device (n = 6 eyes/group and each eye had 6 laser spots). Fourteen days after the CNV procedure, the rats were perfused with 5 mL PBS containing 50 mg/mL fluorescein-labeled dextran (FITC-dextran, MW: 2×10^6; Sigma-Aldrich). Results of mouse CNV experiments [25] indicated that laser-induced CNV lesions were most active at 14 days after laser application and gradually self-resolved more than 28 days after the laser burn. This data was supported by our previous study of laser-burned monkey eyes [28].

We enucleated the eyes in the current study at 14 days after the CNV laser procedure, after euthanizing the animals per the previously described method. The eyes were removed and fixed for 30 minutes in 4% phosphate-buffered PFA. The cornea and lens were removed and the entire retina was carefully dissected from the eyecup. Radial cuts (4 to 6) were made from the edge to the equator, and the eyecup of the RPE-choroid-sclera (R-C-S) complex was flat mounted in Permalfuor (Beckman Coulter; Fullerton, CA, USA) with the scleral side facing down. Flat mounts were examined by fluorescence microscopy (Leica FW4000, Leica Microsystems Japan), and the total area of each CNV zone associated with each burn was measured. The CNV lesions were identified by the presence of fluorescent blood vessels on the choroidal/retinal interface circumscribed by a region lacking fluorescence. This process duplicated past reported procedures [33,34]. Two retinal specialists (HO and TA) and one non-specialist (NN) evaluated the size of the dextran-fluorescein perfused CNVs in a blinded manner, as described above.

Statistical Analyses

Analysis of variance (ANOVA) with Tukey's test was used to examine differences in the leakage and severity of the CNVs in the fluorescein angiograms and the area of the choroidal flat mount. Endothelial tube formation was also evaluated by this method. P-values less than 0.05 were considered significant.

Results

In Vitro Vasohibin-1 Release from the Device

Each result is shown as mean ± SD of three different experiments in Figure 1E. A prominent initial increase was observed in vasohibin-1 pellets (Pellet) and it appeared to almost plateau at 7 days after the start of incubation. A minor increase was observed in the vasohibin-1 delivery devices (VDD) with an almost level release observed over the 28 days of incubation. If we examine the amount released from the device (4×4×1.5 mm) between Days 7 and 28, the amount released was estimated to be 0.31 nM/day in the 10VDD group, 0.070 nM/day in the VDD group, 0.088 nM/day in the pellets, and 0 in the NVDD group (Fig. 1E) in a closed incubation system, when we used 500 mg/mL COLs for the permeable PEG/COLs membranes. These calculations were performed from the fitting line between 0 and 28 days. In rat experiments, the release amount would be less, because we used a smaller device for rats than used in the *in vitro* release assay. The larger device used in the *in vitro* release assay in Fig. 1E had 5.44 times (12.25 mm^2 vs 2.25 mm^2) larger drug-releasing surface area and 3.42 times faster releasing rate than that of the transplanted device used in rats, from the results of Fig. S1. The total amount of vasohibin-1 released from the 10VDD devices during the CNV suppression experiment in rats was estimated grossly to be approximately 4.28 nM over 2 weeks. The total amount of vasohibin-1 during the 2 weeks was estimated as about 14.6 nM from the results of Figure 1E, and was divided by 3.42, which is the difference in releasing rate between *in vitro* release assay and *in vivo* experiments, although the effective amount of vasohibin-1 in CNV suppression would be smaller than 4.28 nM, due to drug elimination from the eye. These results were confirmed by western blotting analysis; Figure 1D shows the representative results at Days 1, 7, 14, and 28. A greater amount of vasohibin-1 was observed in the 10VDD and pellet groups than was seen in the NVDD and VDD groups. The results of the pellet group at Day 1 (1d in Fig. 1D) was obtained after diluting the samples five times, because the concentration was too high to be shown by western blotting. However, the size of the pellets was much smaller after 7 days of incubation.

Endothelial Tube Formation

Endothelial tube formation of HUVECs cultured on the NHDF layer was assessed using anti-human CD31 immunostaining (Fig. 2). We used a range of native vasohibin-1 concentrations (from 0 to 10 nM, using 2 nM VEGF) for the preliminary experiments. After the initial examination, the cells were fixed and stained using anti-human CD31. Figures 2A–2G show representative photographs of the experimental results. Figure 2E shows the results of released vasohibin-1 (0.56 nM) from the devices with 2 nM VEGF. Figure 2H shows the average of each experiment; significantly fewer CD31-positive points were observed in released vasohibin-1-treated wells when compared to those of the vehicle released from the NVDD ($p = 0.000001$) or VEGF-treated control ($p = 0.000002$). Vasohibin-1 released from the device showed activity comparable to the native vasohibin-1.

Macro Examination

FD40 was detected in the device (Figs. S2A and S2B show color and fluorescein photographs, respectively) or in pellets (Figs. S2G and S2H) at the implant site through the conjunctiva in the live rats. When we enucleated the eyes at a week after device implantation, mild fibrosis was observed around the devices (Fig. S2C) and around the pellets (Fig. S2I). Fluorescein photography demonstrated the presence of FD40 in the device, with little fluorescein in the conjunctiva and surrounding tissues (Fig. S2D, arrow). FD40 was also detected in the sclera after removal of the device (Figs. S2E and S2F, arrow). Conversely, FD40 pellets showed strong fluorescein on the conjunctiva and surrounding tissues, as was seen for the pellet itself (Fig. S2J, arrow). Furthermore, little fluorescein was observed on the sclera after removal of the device (Figs. S2K and S2L, arrow). Similar conditions were observed when we examined the tissues at 2 weeks after device and pellet implantation; fluorescence was observed over a wider area for those specimens where the device was implanted compared to results at Week 1 (data not shown).

Immunohistology of Vasohibin-1

In immunostained eyes, vasohibin-1-positivity was found in only the 10VDD group (Fig. 3B), but not in the NVDD group (Fig. 3A) or the negative control without the first antibody (Fig. 3D), mainly at the region where vasohibin-1 releasing devices were placed. Pellets showed strong local immunoreactivity, but no immunoreactivity in the retina (Fig. 3C). Vasohibin-1 positivity was observed in the neural retina and optic nerve (white arrows in Fig. 3B). Strong immunoreactivity was observed in the choroid, RPE, and at the inner layer (such as the ganglion cell layer [GCL]) by magnified photographs after device implantation (Fig. 3E).

Leakage from CNV

Fluorescein angiography results of each group at 1 week after the laser CNV procedure are shown in Figure 4A. The results show that an intravitreal injection of vasohibin-1 on Day 4 after the CNV procedure led to a significant reduction of FA scores when compared to those of NVDD ($p = 0.00014$), pellet ($p = 0.020$), and vehicle injection ($p = 0.040$) (Fig. 4B). The 10VDD implantation led to a significant reduction of FA scores when compared to the result of the NVDD group ($p = 0.00006$). The VDD implantation led to a significant reduction of FA scores when compared to those of NVDD ($p = 0.000017$), pellet ($p = 0.012$), and vehicle injection ($p = 0.026$). Although FA scores of the 10VDD group seemed to be smaller than those of the pellet ($p = 0.065$) and vehicle injection ($p = 0.12$), the results were not significant. Figure 5A shows the FA results at Week 2 in each group. Significantly lower FA scores were observed for the vasohibin-1 intravitreal injection group when compared to those of NVDD ($p = 0.000022$), and vehicle intravitreal injection ($p = 0.0065$). Further, significantly lower FA scores were observed in the 10VDD group when compared to those of NVDD ($p = 0.000003$) and vehicle injection ($p = 0.0080$) (Fig. 5B). Significantly lower FA scores were also observed in the VDD group when compared to those of NVDD ($p = 0.000058$) and vehicle injection ($p = 0.011$).

Flat-mount Examination of the CNV Site

Choroidal flat mounts were prepared 2 weeks after device implantation; representative results of each group are shown in Figure 6A. The area of the CNV was 27,288±7,975 μm^2 for the NVDD group; 23,532±13,120 μm^2 for the VDD group; 17,382±715 μm^2 for the 10VDD group; 30,502±780 μm^2 for the vasohibin-pellet group; 26,900±9,067 μm^2 for the intravitreal vehicle injection group, and 12,731±4,113 μm^2 for the intravitreal vasohibin-1 injection group (Fig. 6B). The CNV area was smaller in eyes that were treated with 10VDD or intravitreal vasohibin-1 injection compared to the other treatments. A significantly smaller CNV area was observed in the 10VDD group when compared to those of the NVDD ($p = 0.0004$), pellet transplantation ($p = 0.0011$), and intravitreal vehicle injection groups ($p = 0.000015$). A significantly smaller CNV area was also